Cipla Ltd.

Financial

	Cipla	Torrent Pharma	Mankind Pharma
Operational Metrics
API Sector
US DMF Filings	2204.0 .	n/a	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	283.0 .	168.0 .	60.0 .
Number of ANDA's Approved By USFDA	204.0 .	132.0 .	44.0 .
Domestic Sales Growth - YoY	7.1 %	12.8 %	n/a
R&D as a % of Total Sales	5.1 %	5.4 %	2.15 %
Financials
5 yr Average ROE	12.48 %	20.0 %	23.46 %
5yr average Equity Multiplier	1.31	2.34	1.37
5yr Average Asset Turnover Ratio	0.78	0.65	0.95
5yr Avg Net Profit Margin	12.29 %	13.21 %	17.9 %
Price to Book	4.42	14.99	10.16
P/E	25.11	60.42	52.6
5yr Avg Cash Conversion Cycle	-4.58 Days	-189.03 Days	-44.05 Days
Inventory Days	58.34 Days	54.5 Days	58.78 Days
Days Receivable	45.49 Days	41.38 Days	24.18 Days
Days Payable	110.05 Days	318.84 Days	130.75 Days
5yr Average Interest Coverage Ratio	33.93	5.79	56.97
5yr Avg ROCE	17.45 %	23.72 %	30.07 %
5yr Avg Operating Profit Margin	21.56 %	29.52 %	24.6 %
5 yr average Debt to Equity	0.07	0.83	0.05
5yr CAGR Net Profit	21.66 %	10.08 %	13.17 %
5yr Average Return on Assets	9.64 %	8.58 %	17.12 %
Shareholdings
Promoter Holding	29.2 %	68.31 %	72.7 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-4.43 %	-2.94 %	-3.8 %
Change in Mutual Fund Holding (3 Yrs)	6.6 %	-2.45 %	5.84 %

Business

	Cipla	Torrent Pharma	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 95.21 New ventures 4.79 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0	Product Wise Break-Up Pain/Analgesics 0 Gynaecology 0 New ventures 0 Brazil 8.98 Neuro/CNS 0 Contract Manufacturing 6.15 Urology 0 Anti-infectives 0 Anti-Diabetic 0 Domestic Formulations 42.15 Cardiovascular 0 Respiratory 0 VMN 0 Pharmaceutical 0 Gastro - Intestinal 0 Dermatology 0 Germany 13.15 US Formulations 20.71 Others 8.86	Product Wise Break-Up Pain/Analgesics 4.0 Gynaecology 10.0 New ventures 0 Brazil/Latam 0 Neuro/CNS 5.0 Contract Manf. 0 Urology 2.0 Anti-infectives 14.0 Anti-Diabetic 9.0 Domestic formulations 0 Cardiovascular 15.0 Respiratory 8.0 VMN 8.0 Pharmaceutical 0 Gastrointestinal 9.0 Dermatology 5.0 Germany/Europe 0 US Formulations 0 Others 11.0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 37.5 Anti-Infective 14.0 Cardiac Science 11.4 Anti - Diabetes 5.6 Gastro Intestinal 5.4 Urology 4.7 Pain Management 3.8 Derma 3.3 Central Nervous System (CNS) 3.3 Ophthalmology 3.0 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 8.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 44.0 North America 27.0 SAGA 14.0 Europe 12.0 Global API 2.0 Rest of the World 0 Emerging Markets 0 Germany 0 USA 0 Brazil 0 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 1.0	Location Wise Break-Up Bangladesh 0 India 56.28 Germany 10.04 Brazil 10.36 North America 0 Emerging Markets 0 Sri Lanka 0 SAGA 0 Global API 0 USA 9.65 Nepal 0 Rest of the World 0 Europe 0 Others 13.67	Location Wise Break-Up Bangladesh 0 India 86.0 Germany 0 Brazil 0 North America 0 Emerging Markets 0 Sri Lanka 0 SAGA 0 Global API 0 USA 0 Nepal 0 Rest of the World 0 Europe 0 Others 14.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 97.83 New Ventures 2.17	-	-
Asset Break-Up	Asset Break-Up India 46.99 USA 30.03 South Africa 18.71 Others 4.27	Asset Break-Up India 96.58 USA 0.32 South Africa 0 Others 3.1	-

Cipla Ltd.

SIGN UP FOR FREE